EU Drug Approval Revoked Over Trial Data Integrity: Lessons From Tavneos for Licensors and Licensees

A US company licensing European rights to its medicine must distinguish the procedures for losing an approval from the contractual allocation of that loss. Section 505(e) of the Federal Food, Drug, and Cosmetic Act requires due notice and an opportunity for a hearing before the FDA withdraws approval of a new drug application, allows an immediate suspension only on a finding of an imminent hazard to public health, and lists grounds that run from new safety evidence to untrue statements in the application.121 U.S.C. § 355(e) (section 505(e) of the Federal Food, Drug, and Cosmetic Act); 21 C.F.R. § 314.150(a)(1)–(2) and § 314.200(g). Food and Drug Administration, 'ChemoCentryx, Inc.; Proposal To Withdraw Approval of New Drug Application for TAVNEOS (Avacopan) Capsule, 10 Milligrams; Opportunity for a Hearing' (Docket No FDA-2026-N-1321), 91 Fed Reg 23278 (30 April 2026), at I.A–B and II (proposed withdrawal for insufficient evidence of effectiveness and untrue material statements; a hearing request is not an entitlement to a hearing). A license addressing recalls, safety signals or restricted indications may leave a different evidentiary problem unresolved. On 4 August 2026 the European Commission revoked the EU marketing authorization of the orphan medicine Tavneos (avacopan), with the reliability of its pivotal trial data central to the decision. The European Medicines Agency's human medicines committee had found that the data submitted from the single pivotal study were "incorrect and misleading", because of how the study sponsor handled its database after the first database lock in November 2019.2Commission Implementing Decision C(2026) 5725 final of 4 August 2026 (Tavneos, EU/1/21/1605), Art. 1–2 and Annex, scientific conclusions, pp 2–4 (incorrect particulars, unreliable pivotal-study results and negative benefit-risk balance). The decision was addressed to the company in the European licensee's group that held the authorization. The trial had been run by the US originator. The EU findings concerned the reliability of the pivotal evidence, rather than a newly identified manufacturing defect. Loss of that evidentiary basis raises allocation questions that license, supply and acquisition agreements may not expressly resolve.

1. Why Was the EU Approval Revoked?

Tavneos was authorized in the European Union on 11 January 2022, on a full application under Art. 8(3) of Directive 2001/83/EC, for adults with severe, active granulomatosis with polyangiitis or microscopic polyangiitis in combination with a rituximab or cyclophosphamide regimen. The application rested on one phase 3 study, ADVOCATE, sponsored by ChemoCentryx, with two supportive phase 2 studies.2 According to the scientific conclusions annexed to the Commission's decision, the European Medicines Agency became aware in January 2026 of new information about the sponsor's handling of the ADVOCATE database, and on 29 January 2026 the Commission opened a procedure under Art. 20 of Regulation (EC) No 726/2004. That article has the Commission request the Agency's opinion, here on whether the authorization should be maintained, varied, suspended or revoked, requires that the holder be invited to give oral or written explanations wherever practicable, and ends in a final decision adopted by implementing act.3Regulation (EC) No 726/2004 [2004] OJ L136/1, Art. 14(1) and (2), Art. 20(1) to (3), (7) and (8). The procedure is not reserved for safety questions. Art. 20(8) of Regulation (EC) No 726/2004 routes the opinion through the Pharmacovigilance Risk Assessment Committee only where the procedure began with the evaluation of pharmacovigilance data, and this one began with a question about a database.

The findings of the CHMP are specific. Sponsor personnel reviewed unblinded efficacy data after the initial database lock of 5 November 2019 and saw that superiority at week 52 had not been demonstrated. Nine patients were then re-adjudicated "based on knowledge of treatment outcomes", and the rerun of the primary analysis turned a non-significant result into a statistically significant one. The committee found that neither the original analysis nor the changes made after unblinding had been disclosed in the application or in later procedures, that the clinical study report had stated that the protocol's unblinding process was followed, and that the handling did not comply with GCP principles as the ICH E6 and E9 guidelines express them, in a way whose impact "cannot be isolated to a certain part of the data".2 It rejected the holder's position that the re-adjudication corrected genuine errors and that the data at the initial lock could be relied on, observing that even those data showed non-inferiority rather than the superiority that had been "an important deciding factor" in the original grant. The New England Journal of Medicine, which had published the ADVOCATE results in 2021, retracted the article on 29 June 2026.4EJ Rubin, “Retraction: Jayne DRW et al. Avacopan for the Treatment of ANCA-Associated Vasculitis, N Engl J Med 2021;384:599-609”, N Engl J Med, published online 29 June 2026, doi:10.1056/NEJMe2608684.

The legal grounds matter beyond this particular decision. Art. 20(1) of Regulation (EC) No 726/2004 opens the procedure where a measure envisaged in Titles IX and XI of Directive 2001/83/EC should be applied to a centrally authorized product, and Art. 116 of Directive 2001/83/EC, in Title XI, contains two different rules. Its first paragraph obliges the competent authority to suspend, revoke or vary an authorization where the product is harmful, lacks therapeutic efficacy, has an unfavorable risk-benefit balance or is not of the declared composition. Its second paragraph allows, without obliging, the same measures on further grounds, among them that the particulars supporting the application under Art. 8 of Directive 2001/83/EC are incorrect.5Directive 2001/83/EC [2001] OJ L311/67, Art. 8(3)(i) and Art. 116. The CHMP relied on both. It found the risk-benefit balance "not favourable" and the particulars "incorrect", and recommended revocation "pursuant to Article 116 of Directive 2001/83/EC". The committee also considered serious liver risks, including drug-induced liver injury and vanishing bile duct syndrome with fatal cases. New hepatic-risk information arrived during the referral, and the latest periodic safety review recommended stricter monitoring. With the pivotal efficacy evidence considered unreliable, the CHMP could no longer establish that benefit outweighed those risks.2 The data-integrity findings were central to that conclusion; the assessment did not assume a static safety record.

The EU courts have reviewed revocations before, on different facts. In Artegodan, construing the predecessor provision in Directive 65/65/EEC, the Court of First Instance held that the burden lies on the competent authority to show that a condition for withdrawal is met and that, leaving aside the exceptional case in which the authority gives a detailed acknowledgement that it had assessed the product incorrectly when granting it, a withdrawal is in principle justified only where a new potential risk or the lack of efficacy is substantiated by "new, objective, scientific and/or medical data or information".6Joined Cases T-74/00 and others, Artegodan GmbH and Others v Commission [2002] ECR II-4945, paras 77, 191–194 and 199–201 (withdrawal grounds, interim relief and limits of judicial review). That judgment concerned a different scientific reassessment. Tavneos presents new information about old data, together with a committee finding that the grant rested on incorrect particulars. Artegodan did not decide how its reasoning applies to database-integrity findings of this kind; its reference to new information does not itself exclude them.

An approval can be lost while the molecule and its manufacture stay the same, because the evidence behind it has been found wanting. A contract that prices regulatory risk as a property of the product may not reach that loss.

The contrast with the United States is procedural as much as substantive. The FDA's Center for Drug Evaluation and Research proposed, in a notice published in the Federal Register on 30 April 2026, to withdraw approval of the Tavneos new drug application on two grounds that track Art. 116 of Directive 2001/83/EC closely: a lack of substantial evidence of effectiveness in light of the new information, under section 505(e)(3) of the Federal Food, Drug, and Cosmetic Act, and untrue statements of material fact in the application, under section 505(e)(5) of that Act.1 ChemoCentryx, which Amgen acquired in 2022, requested a hearing on 1 June 2026 and filed supporting data on 23 July 2026. Amgen's quarterly report states that the product remains on the US market while the process is pending, but a hearing may be denied and approval withdrawn.7Amgen Inc., Quarterly Report on Form 10-Q for the period ended 30 June 2026 (filed 5 August 2026), p 16, note 8, ‘TAVNEOS developed-product-technology rights’, and p 54, risk factors (hearing requested on 1 June and supporting material submitted on 23 July 2026; Amgen’s position and its conditional recoverability assessment). The Commission's decision, by contrast, took effect on notification to its addressee under Art. 297(2) TFEU, and under Art. 278 TFEU an action against it before the General Court would not, of itself, suspend it.8Art. 263, Art. 278, Art. 279 and Art. 297(2) TFEU [2016] OJ C202/47. Switzerland took a third course. A DHPC issued by the Swiss holder in coordination with Swissmedic, dated 9 September 2026 and published by Swissmedic on 10 September, states that Swissmedic assessed the risk-benefit balance as negative on account of the GCP breaches and growing concerns about hepatotoxicity, and that the Swiss authorization is revoked with effect from 30 November 2026.9Vifor Fresenius Medical Care Renal Pharma Ltd. in coordination with Swissmedic, 'Tavneos (Avacopan): Negatives Nutzen-Risiko-Verhältnis – Widerruf der Zulassung' (DHPC, 9 September 2026; published 10 September 2026); Vifor Fresenius Medical Care Renal Pharma Ltd. in coordination with Swissmedic, 'Tavneos (Avacopan): Medikamentös bedingte Leberschädigung und Gallengangverlustsyndrom – verschärfte Überwachung der Leberfunktion' (DHPC, 5 August 2026; published 6 August 2026); Swissmedic, Swiss Public Assessment Report: Tavneos (10 November 2022), p 1 and section 2.1 (Swiss authorization and orphan chronology; negative risk-benefit assessment and revocation announced for 30 November 2026).

2. The Licensee Holds the Authorization, the Licensor Held the Database

The European authorization was never held by the company that ran the trial. ChemoCentryx's annual report for 2021 describes a collaboration and license agreement signed with Vifor in May 2016 for avacopan in orphan renal diseases in Europe and certain other markets, with initial consideration of USD 85 million, comprising USD 60 million in cash and a USD 25 million equity investment. A February 2017 letter agreement provided for an extension to markets outside the United States and China, implemented by an amendment of 22 May 2017; a June 2018 letter added China. The report lists regulatory and sales milestones, royalties in a range from the teens to the mid-twenties, a manufacturing and supply agreement of October 2020 under which ChemoCentryx supplied avacopan to Vifor for commercial use outside the United States, and a right for Vifor to terminate at its convenience, and it records a USD 45 million milestone earned on the Commission's approval in January 2022.10ChemoCentryx, Inc., Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (filed 1 March 2022), Part I, Items 1 and 1A, and Note 12. Public exhibits: ChemoCentryx, Inc./Vifor (International) Ltd., Collaboration and License Agreement of 9 May 2016; February 2017 CCX168 letter agreement; Amendment of 22 May 2017 with Vifor Fresenius Medical Care Renal Pharma Ltd.; CCX168 letter agreement of 6 June 2018; and ChemoCentryx, Inc./Vifor Fresenius Medical Care Renal Pharma Ltd., Manufacturing and Supply Agreement of 29 October 2020. The 2016 license and 2020 supply agreement select New York law. The historical, partly redacted disclosures do not establish the complete operative contract chain in September 2026. CSL's announcements describe the arrangement as a collaboration and license agreement between Vifor Fresenius Medical Care Renal Pharma Ltd. and ChemoCentryx, under which the product is commercialized outside the United States.11Vifor Fresenius Medical Care Renal Pharma and CSL, news releases of 26 June and 6 August 2026 on the Tavneos revocation recommendation and Commission decision (commitment to implement the outcome, not an express admission of findings or liability). The EU holder, and the addressee of the Commission's decision, is Vifor Fresenius Medical Care Renal Pharma France;2 the Swiss holder is Vifor Fresenius Medical Care Renal Pharma Ltd.9 One pivotal database therefore stands behind authorizations and contracts involving different companies in different jurisdictions. The European and Swiss authorization decisions address the holders; the contractual allocation of the resulting loss is a separate matter.

The referral made the holder answer for the sponsor. The CHMP's list of questions of 29 January 2026, addressed to the holder, required it to describe "in a detailed, clear, and precise manner" the handling of the ADVOCATE database: the database locks, the unblinding process, the roles and data access of unblinded sponsor personnel and what the adjudication committee was given after the locks. It also required the holder to share any information requested by, provided to or received from other regulatory agencies about the study. The timetable set 16 February 2026 for the answers.12EMA/CHMP, Tavneos referral under Art. 20 Regulation (EC) No 726/2004 EMA/REF/0000325221: List of questions (29 January 2026), Questions 2–3; timetable (26 March 2026); Assessment report EMADOC-1700519818-3237424 (25 June 2026), sections 2.2.1 and 2.2.3, pp 16 and 19–21. Those requests concern records held or created by the sponsor, its CRO and an adjudication committee. They show why the holder needs reliable access arrangements, without establishing that contractual rights are its only possible source of access. Clinical-trial law separately preserves the sponsor's responsibility when it delegates tasks. Art. 7(1) of Directive 2005/28/EC, the good clinical practice directive in force while ADVOCATE ran, allowed a sponsor to delegate any of its trial functions but kept it responsible for ensuring that the conduct of the trial and the final data complied, and Art. 71 of the EU Clinical Trials Regulation keeps that rule today.13Art. 7(1) Directive 2005/28/EC [2005] OJ L91/13; Art. 71 EU CTR [2014] OJ L158/1. Neither instrument makes the company that later holds the authorization a sponsor. The revocation fell on the holder all the same.

The CHMP's assessment report adds a fact that may matter more to the parties than it did to the regulator. The holder informed the Agency that its staff had been copied on correspondence between the sponsor and the holder of the Japanese authorization about a June 2021 inspection by Japan's Pharmaceuticals and Medical Devices Agency, and the committee read that correspondence as showing that staff of the EU holder "had visibility of certain elements of the inspection discussions, including matters relating to re-adjudication and the initial DBL".12 The committee cited it as evidence of a lack of transparency in trial communications. Between licensor and licensee the same sentence bears on something else: what the licensee's group knew, when, and through whom, which is the fact on which periods for avoiding a contract, fraud carve-outs and defenses of reliance usually turn. ChemoCentryx's report records that Vifor had sublicensed Japan to Kissei.10

The parties then took different positions in different forums. Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL stated on 26 June and again on 6 August 2026 that they respect the outcome of the regulatory process and are committed to implementing it in full.11 Amgen states that it continues to believe that the product demonstrates clinical effectiveness and a favorable benefit-risk profile, and its submission to the FDA includes an independent, blinded re-adjudication of certain ADVOCATE data.7 The CHMP had before it a retrospective re-adjudication by the Duke Clinical Research Institute's Clinical Events Classification group and reported that it confirmed non-inferiority at weeks 26 and 52 but did not show superiority at either point against the prespecified threshold.12 Whether that is the exercise the FDA is being asked to weigh cannot be read from the public record. The public positions differ: the licensor contests the US proposal while the licensee's group has committed to implementing the EU decision. That commitment does not establish acceptance of every factual finding or waiver of private claims. The EU procedure's list of questions asked the holder to disclose what other regulators had been told.

3. Challenging Revocation or Applying Again: Later Evidence and Orphan Exclusivity

The first route back runs through the General Court. Under the fourth paragraph of Art. 263 TFEU the holder, as addressee, may bring an action for annulment, and under the sixth paragraph of Art. 263 TFEU it must do so within two months of notification.8 Art. 60 of the General Court's Rules of Procedure adds a single period of ten days on account of distance to this time limit, and Art. 58 of those Rules counts a period expressed in months and days first in whole months and then in days, leaving out the day of the triggering event.14Art. 58, Art. 59 and Art. 60 Rules of Procedure of the General Court [2015] OJ L105/1. The cited decision and company announcements do not state when the decision of 4 August 2026 was notified. Counted from notification on the day of adoption, the period runs to Wednesday, 14 October 2026, and a later notification moves it later. Where time runs from publication in the Official Journal instead, Art. 59 of the Rules starts it at the end of the fourteenth day after publication, but the applicable starting event depends on the challenged act and the applicant.14 A licensor that is not the addressee would have to show that the decision is of direct and individual concern to it, and whether a company whose royalties depend on another company's authorization meets that test is a question the Treaty text leaves open. The holder's announcement of 6 August 2026 mentioned no action and said that it would implement the decision in full.

An annulment action would seek review of legality, including the legally relevant assessment of the evidence, rather than a fresh marketing-authorization assessment. The application for interim measures that Art. 278 and Art. 279 TFEU allow is a separate request with its own hurdles. The anorectics litigation that produced Artegodan shows how uncertain that route is: seven suspension orders made at first instance were set aside on appeal by the President of the Court of Justice before the main judgment was given.6 The public record includes evidence the CHMP has already weighed. The Duke re-adjudication and the post hoc programmatic analyses were before the committee and did not show superiority, and of the post-marketing evidence, including the post-authorization safety study AVACOSTAR, the committee concluded that it "cannot replace the evidence from an adequately designed and GCP-compliant phase 3 study".2

The second route is a new application, and the CHMP's own reasoning shows how long it is. The authorization granted in January 2022 would have expired in January 2027 unless renewed under Art. 14(1) and (2) of Regulation (EC) No 726/2004, and renewal requires a re-evaluation of the risk-benefit balance on a consolidated file submitted at least nine months before expiry.3 The committee recorded that the holder had no ongoing or planned study adequately designed to replace ADVOCATE before that date, that a new post-authorization efficacy study the holder had mentioned had "no bearing" on its conclusion, and that it "could not identify any condition that could be fulfilled to demonstrate a positive benefit-risk balance".2 Once an authorization is revoked, there is nothing left to vary or renew. If the revocation stands, renewed authorization would require a fresh application with adequate supporting evidence. The CHMP's assessment indicates the scale of that evidentiary problem; it does not establish in advance what a future application would contain or how it would be decided.

Orphan Designations After Revocation

Orphan designation and market exclusivity raise distinct questions. Avacopan holds two orphan designations, EU/3/14/1372 for microscopic polyangiitis and EU/3/14/1373 for granulomatosis with polyangiitis, granted in November 2014 and transferred to the French VFMCRP company in 2020. Art. 8(1) of the Orphan Regulation attaches ten years of market exclusivity to the grant of the authorization, whose ordinary ten-year period for Tavneos would have reached January 2032, subject to the statutory reduction and derogations. Art. 5(12) of the Orphan Regulation removes a designation from the register at the sponsor's request, before authorization where the criteria are no longer met, or at the end of market exclusivity, and none of the three describes a revocation. The register's entries still list both designations as active and record no step after 2021.15Regulation (EC) No 141/2000, Art. 5(12) and 8(1)–(3); Commission guideline ENTR/6283/00 Rev 5 (July 2021), section D, p 11 (orphan criteria reviewed before marketing authorisation); register entries EU/3/14/1372 and EU/3/14/1373. Before the authorization was granted, the Committee for Orphan Medicinal Products (COMP) recommended on 12 November 2021 that neither designation be removed from the register. It found significant benefit on the strength of the ADVOCATE results, first among them sustained remission at week 52 in 65.7 percent of the avacopan group against 54.9 percent of the comparator group, "P=0.0066 for superiority".16EMA/COMP, Orphan Maintenance Assessment Report: Tavneos (EMADOC-1700519818-748110, 11 January 2022), sections 3–4, pp 10–12 (significant benefit and the COMP positions of 12 November 2021). That is the superiority the CHMP later found was never demonstrated.

A fresh application seeking authorization as an orphan medicine would ordinarily require a maintenance assessment of the orphan criteria, including significant benefit over currently satisfactory methods. The Commission's guidance expressly requires that assessment before authorization. The cited provisions do not expressly settle how this revocation affects the existing exclusivity period or whether any later authorization could begin a new one. Art. 8(3)(b) of the Orphan Regulation permits authorization of a similar product for the same indication where the original holder cannot supply sufficient quantities; that provision does not expressly determine the consequences of revocation. Active designation entries alone therefore do not establish the exclusivity available for a second application.15

Revocation also changes the basis for national reimbursement, through separate national rules. In Germany, § 35a Abs. 1 Satz 11 SGB V ordinarily treats the added benefit of a medicine authorized under the Orphan Regulation as proven by the authorization itself. If its relevant statutory-insurance turnover exceeds EUR 30 million in the preceding twelve calendar months, § 35a Abs. 1 Satz 12 SGB V requires evidence of added benefit against the appropriate comparator on request. The Federal Joint Committee (G-BA) had found a hint of a minor added benefit for avacopan in its decisions of 4 August and 27 September 2022, and an annex to the reimbursement agreement under § 130b SGB V between the GKV-Spitzenverband and Fresenius Nephrologica recognized prescriptions as a practice particularity from 1 May 2023 on the strength of those decisions. After the threshold was exceeded, the G-BA reassessed avacopan and on 5 March 2026 replaced the 2022 findings with a finding that an added benefit is not proven, on grounds that concerned the comparator therapy in ADVOCATE rather than the integrity of its data.17Sozialgesetzbuch (SGB) Fünftes Buch (V), Gesetzliche Krankenversicherung vom 20. Dezember 1988 (BGBl. I S. 2477, 2482), § 35a Abs. 1 Satz 11–12 SGB V and § 130b SGB V; GKV-Spitzenverband and Fresenius Nephrologica, Anlage zur Vereinbarung nach § 130b Abs. 1 Satz 1 SGB V zum Arzneimittel Tavneos (Wirkstoff: Avacopan) bezüglich der Anerkennung einer Praxisbesonderheit (recognition from 1 May 2023); Gemeinsamer Bundesausschuss, Beschluss über eine Änderung der Arzneimittel-Richtlinie: Anlage XII, Avacopan (Neubewertung eines Orphan Drugs nach Überschreitung der 30 Millionen Euro-Grenze) (5 March 2026), BAnz AT 30.03.2026 B3, pp 1–2, and Gemeinsamer Bundesausschuss, Tragende Gründe zum Beschluss über Avacopan (5 March 2026), pp 3 and 7–9 (reassessment after the turnover threshold; added benefit not proven on comparator grounds). In Switzerland, Art. 65(1) KVV admits a medicine to the Spezialitätenliste only with a valid Swissmedic authorization, and Art. 68(1)(a) KVV strikes a listed medicine that no longer meets every admission condition; the Swiss holder's group had announced reimbursement from 1 January 2025.18Verordnung über die Krankenversicherung (KVV) vom 27. Juni 1995 (SR 832.102), Art. 65(1) KVV and Art. 68(1)(a) KVV; CSL Vifor and Vifor Fresenius Medical Care Renal Pharma, 'Tavneos (Avacopan) in der Schweiz jetzt erstattet für die Behandlung der ANCA-assoziierten Vaskulitis' (Fribourg, 6 February 2025) (authorization condition, deletion rule and announced reimbursement from 1 January 2025). Whether a reimbursement amount negotiated on the ADVOCATE evidence is revisited is a separate question, and the revocation decisions do not answer it.

Switzerland: Revocation Timing and the Suspensive Effect of an Appeal

Switzerland is not an EU Member State, and its authorization follows its own path. The Swiss authorization, number 66772, was granted on 19 September 2022 in a work-sharing procedure with Canada, and Swiss orphan status had been granted on 20 September 2017.9 Art. 4(1)(a decies)(2) HMG recognizes the foreign orphan status of a medicine or its active substance where the recognizing country has comparable medicines control. Art. 11b(4) HMG provides fifteen years of document protection on application for an important medicine for rare diseases. Art. 16c HMG allows Swissmedic to review an authorization at any time and to adapt or revoke it, and Art. 66(2)(b) HMG lists revocation among its administrative measures; the DHPC does not say which provision Swissmedic applied.19Bundesgesetz über Arzneimittel und Medizinprodukte (Heilmittelgesetz, HMG) vom 15. Dezember 2000 (SR 812.21), Art. 4(1)(a decies)(2) HMG, Art. 11b(4) HMG, Art. 16c HMG, Art. 66(2)(b) HMG and Art. 84(1) HMG (orphan status, protection on application, review and revocation powers, and legal protection). Under Art. 84(1) HMG the procedure and legal protection follow, among other acts, the VwVG. An appeal must be lodged within thirty days of notification under Art. 50(1) VwVG. It has suspensive effect by default under Art. 55(1) VwVG, but Swissmedic or, after filing, the appeal body may withdraw that effect under Art. 55(2) VwVG; restoration may be sought under Art. 55(3) VwVG.20Bundesgesetz über das Verwaltungsverfahren (Verwaltungsverfahrensgesetz, VwVG) vom 20. Dezember 1968 (SR 172.021), Art. 50(1) VwVG and Art. 55(1)–(3), (5) VwVG (thirty-day appeal period and default suspensive effect, subject to withdrawal and possible restoration). The communication does not say whether suspensive effect was withdrawn. Were one company in a group to implement the EU decision while another appealed against the Swiss ruling, the group would take positions on the same record in two forums, with the fixed date of 30 November 2026 running in the background.

4. Allocating Loss Through Warranties, Indemnities, Milestones and Supply Terms

Between licensor and licensee, the first question is not what the contract says about data but when it said it. The Tavneos chronology shows the pattern. The license was signed in May 2016, with territorial-extension documents in 2017 and 2018, the database was locked and re-adjudicated in November 2019, the manufacturing and supply agreement followed in October 2020, the authorization was granted in January 2022, and the Agency learned of the handling in January 2026. A representation about the accuracy and GCP compliance of existing clinical data must be read for its temporal scope: a statement confined to signing does not automatically cover later trial conduct. Continuing covenants can require GCP-compliant development, disclosure of findings and delivery of complete and accurate filing data. The distinction matters where the agreement assigns different remedies, exclusions or survival periods to those obligations. The public record includes the 2016 license, territorial-extension documents and the 2020 supply agreement. The license and supply agreement select New York law and disclose continuing compliance duties and limits on remedies. Their redactions and possible later changes prevent treating them as the complete operative contract chain in September 2026.10 The Swiss and Delaware rules below are comparisons for contracts governed by those laws, not conclusions about the Tavneos parties' remedies.

Non-refundable payment terms make recovery harder, but do not resolve every claim. The disclosed license labels its cash upfront fee and regulatory milestones non-refundable, and ChemoCentryx reported the EU-approval milestone as achieved in January 2022.10 Whether a payment made for an approval later revoked because the particulars were incorrect can be reclaimed depends on the governing law and on the theory. For a contract governed by Swiss law, Art. 28(1) OR concerns deception inducing its conclusion. Later trial conduct alone cannot establish deception when an earlier contract was signed; an agreement made after that conduct requires a separate inquiry into inducement, disclosure and knowledge. The one-year period of Art. 31 OR runs from discovery, and under Art. 31(3) OR ratifying the contract does not of itself exclude a damages claim. Art. 97(1) OR addresses damage caused by non-performance or improper performance, unless the debtor proves the absence of fault.21Bundesgesetz betreffend die Ergänzung des Schweizerischen Zivilgesetzbuches (Fünfter Teil: Obligationenrecht, OR) vom 30. März 1911 (SR 220; consolidation of 1 January 2026), Art. 28(1), Art. 31(1) to (3), Art. 97(1), Art. 100(1), Art. 119(1) and Art. 199 OR. Illustrations for Swiss-law contracts; the disclosed Tavneos license and supply agreement select New York law. A lost royalty stream does not by itself establish a claim against the licensee: the payment and termination terms, a legally relevant breach and causation must be examined. A licensee seeking lost margin must likewise address the applicable exclusions, the classification of the loss and any exceptions.

Caps and exclusions can constrain recovery. Their reach depends on the agreed wording, the classification of the loss and mandatory rules of the governing law; any exception for fraud, willful misconduct or gross negligence must be examined separately. For the obligor's own liability, Art. 100(1) OR makes void an advance agreement excluding liability for unlawful intent or gross negligence, and Art. 199 OR invalidates an agreement limiting warranty in a sale where the seller fraudulently concealed the defect.21 Delaware draws a different boundary in acquisition contracts. In ABRY Partners, the Court of Chancery would not enforce a limit insulating the seller from its own knowing participation in false contractual representations; lesser fault did not suffice to escape the agreed remedy limit.22ABRY Partners V, L.P. v. F & W Acquisition LLC, 891 A.2d 1032, 1064–65 (Del. Ch. 2006), opinion of 14 February 2006, pp 54–56 and note 86. Knowing participation in false contractual representations; lesser fault and reasonable reliance distinguished. A Delaware illustration, not a ruling on Tavneos. The contractual wording and factual findings both matter. The CHMP's regulatory assessment does not itself establish the conditions of a private-law claim or an exception to a contractual remedy limit.

The scope of a supply warranty cannot be inferred from physical conformity alone. The disclosed 2020 agreement addresses manufacturing specifications, applicable-law compliance and the allocation of regulatory approvals. Whether revocation creates a warranty breach, triggers a remedy or excuses a remaining obligation depends on those terms, the relevant timing and the governing law.10 Firm orders, minimum purchase commitments, forecasts and any termination or force majeure provisions must also be checked for stranded-inventory exposure. The terms may treat revocation caused by a supplier's trial conduct differently from a regulator's reassessment. For a Swiss-law contract, Art. 119(1) OR extinguishes an obligation to the extent performance becomes impossible through circumstances for which the debtor is not responsible; revocation does not automatically establish those conditions.21 Third-party liability depends on the applicable regime and each entity's role; regulatory revocation does not itself establish a civil claim. An indemnity also requires the claim to fall within its wording and applicable causal conditions.

The referral shows why regulatory-cooperation terms matter. It asked the holder, within weeks, for the sponsor's database history, the roles of its unblinded staff and what it had exchanged with other regulators. A clause that gives the licensee access to the trial master file, the database audit trail and the adjudication records, and obliges the licensor to produce them on a regulator's timetable, can be critical to obtaining the information needed to answer in time. The CRO sits one link further out. The CHMP found that the integrity of the earlier data could not be guaranteed because they were "managed by the same parties, mainly the sponsor and service provider", and pointed to "a general and unsound quality culture within the organisation(s) involved in the study conduct".12 If the licensee has neither a direct agreement nor another enforceable right against that service provider, access and recourse may depend on the sponsor's contract and its own rights against the sponsor. The CRO agreement's audit, inspection and record-retention terms must therefore be checked against the holder's regulatory needs.

Acquirers meet the same facts from the other end. Amgen acquired ChemoCentryx in 2022, after both the US and the EU approvals. Its quarterly report for the period ended 30 June 2026 records a carrying value of USD 2.4 billion for the Tavneos developed-product-technology rights, USD 2.3 billion of it related to the US market, and states that its evaluation indicated the carrying value remained recoverable, while noting that future changes to estimated cash flows could affect that conclusion.7 An acquirer must establish which representations and remedies survive closing; where contractual indemnities are unavailable, diligence and price become particularly important. The facts on which the regulators acted sat in a database audit trail, adjudication committee correspondence and inspection exchanges from 2019 to 2021, records that due diligence should examine and that regulators may request years after approval. For an acquirer of a licensee, or of a portfolio of in-licensed European rights, the questions run the other way: whether the licensee's rights against the originator survive a change of control, and whether the originator's cooperation obligations run to the new owner.

5. For US Licensors, EU Licensees and Acquirers

The identity and responsibilities of each company matter before any claim can be assessed. Which company holds each authorization, which sponsored each pivotal study, and which controls the database, the adjudication records and the contract with the research organization can have different answers. The Tavneos procedure required the holder to answer for evidence generated by other entities. Whether a license gives the holder a right to the sponsor's audit trail and unblinding logs on a regulator's timetable, and whether the sponsor's agreement with its CRO lets the sponsor honor that right, can be read from the agreements. Whether those agreements were drafted with an eighteen-day list of questions in view is a different matter.

Recovery depends on the contractual allocation and on facts that the agreement alone cannot establish. Whether a data-integrity representation was given only at signing or brought down at each milestone, whether development covenants extend to the handling of a database after lock, and whether the cap and the consequential-loss exclusion carve out fraud and gross negligence in terms the governing law would enforce are central to the recovery analysis. A paid regulatory milestone, royalties that stop with sales, inventory ordered against a forecast and the cost of an orderly withdrawal may engage different clauses, and the same regulatory finding may affect them all. Where one party contests a proposed withdrawal while another implements a separate revocation, their cooperation and joint-defense terms may affect how they share and use submissions. Those terms do not determine what a regulator or court may admit in evidence, and implementation alone is not an admission of the findings.

The parties also face different procedural and contractual clocks. The annulment period for the Commission's decision, counted from a notification on the day of adoption, closes in mid-October 2026. An appeal against a Swissmedic ruling must be lodged within thirty days of its notification, and the Swiss revocation is announced to take effect on 30 November 2026. Amgen's August report described the FDA proceeding as pending. If Swiss law governs a deception claim, Art. 31 OR gives the induced party one year from discovery to declare that it will not be bound or demand restitution. Public disclosure of allegations, discovery of the deception by the relevant party and legally attributable knowledge are distinct questions; the public chronology does not establish a particular party's discovery date. Contractual notice periods, limitation clocks and the survival of indemnities each run from a different event, and the same chronology can have different legal consequences for each.

For a US-listed licensor or acquirer, the findings also raise disclosure and accounting questions. A withdrawal under section 505(e)(5) of the Federal Food, Drug, and Cosmetic Act rests on a finding that an application contained untrue statements of material fact, a finding that may require reassessment of securities disclosures, asset values and oversight, subject to the applicable rules and materiality. Amgen's report already links the jurisdictions, noting that decisions or recommendations of regulators outside the United States, the CHMP's among them, could adversely affect regulatory assessments elsewhere.7 A European licensee must also consider how findings about the originator's data could be used in a US proceeding about the same study; admissibility and weight depend on that proceeding.